Biogen Inc.
BIIB
$146.58
$2.811.96%
| Weiss Ratings | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.71 | |||
| Price History | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.17% | |||
| 30-Day Total Return | 2.68% | |||
| 60-Day Total Return | -7.96% | |||
| 90-Day Total Return | -19.89% | |||
| Year to Date Total Return | -2.28% | |||
| 1-Year Total Return | -32.63% | |||
| 2-Year Total Return | -45.76% | |||
| 3-Year Total Return | -28.77% | |||
| 5-Year Total Return | -53.90% | |||
| 52-Week High % Change | -39.59% | |||
| 52-Week Low % Change | 11.87% | |||
| Price | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $238.00 | |||
| 52-Week Low Price | $128.51 | |||
| 52-Week Low Price (Date) | Feb 12, 2025 | |||
| 52-Week High Price (Date) | Jul 12, 2024 | |||
| Valuation | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 21.04B | |||
| Enterprise Value | 25.39B | |||
| Price/Earnings (TTM) | 12.86 | |||
| Earnings Per Share (TTM) | 11.18 | |||
| Earnings Per Share Growth | 40.06% | |||
| Price/Earnings To Growth | 0.32 | |||
| Price/Sales (TTM) | 2.17 | |||
| Price/Book (Q) | 1.25 | |||
| Enterprise Value/Revenue (TTM) | 2.62 | |||
| Price | $146.58 | |||
| Enterprise Value/EBITDA (TTM) | 8.09 | |||
| Enterprise Value/EBIT | 10.30 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 146.10M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (617) 679-2000 | |||
| Address | 225 Binney Street Cambridge, MA 02142 | |||
| Website | www.biogen.com | |||
| Country | United States | |||
| Year Founded | 1978 | |||
| Profitability | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 25.47% | |||
| Profit Margin | 16.86% | |||
| Management Effectiveness | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.61% | |||
| Return on Equity | 10.36% | |||
| Income Statement | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 9.68B | |||
| Total Revenue (TTM) | 9.68B | |||
| Revenue Per Share | $66.23 | |||
| Gross Profit (TTM) | 7.45B | |||
| EBITDA (TTM) | 3.14B | |||
| EBIT (TTM) | 2.47B | |||
| Net Income (TTM) | 1.63B | |||
| Net Income Avl. to Common (TTM) | 1.63B | |||
| Total Revenue Growth (Q YOY) | 2.87% | |||
| Earnings Growth (Q YOY) | 7.15% | |||
| EPS Diluted (TTM) | 11.18 | |||
| EPS Diluted Growth (Q YOY) | 6.30% | |||
| Balance Sheet | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.38B | |||
| Cash Per Share (Q) | $16.26 | |||
| Total Current Assets (Q) | 7.46B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 16.72B | |||
| Current Ratio (Q) | 1.349 | |||
| Book Value Per Share (Q) | $114.65 | |||
| Total Assets (Q) | 28.05B | |||
| Total Current Liabilities (Q) | 5.53B | |||
| Total Debt (Q) | 6.72B | |||
| Total Liabilities (Q) | 11.33B | |||
| Total Common Equity (Q) | 16.72B | |||
| Cash Flow | BIIB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -799.20M | |||
| Cash from Financing (TTM) | -683.50M | |||
| Net Change in Cash (TTM) | 1.33B | |||
| Levered Free Cash Flow (TTM) | 3.36B | |||
| Cash from Operations (TTM) | 2.88B | |||
